Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, nine have...